LGND

Ligand Pharmaceuticals Incorporated · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-27

Figures on this page computed 2026-11-08 13:29 UTC

Last close

316.13USD

Market data, 2026-11-04

LGND: weekly closes from 202.48 on 2025-11-07 to 316.13 on 2026-11-04, a move of +56.1%. Prices in USD.

Weekly closes, 2025-11-07 to 2026-11-04

Over that span: +56.1%

Except where said otherwise: 10-K for 2025, filed 2026-02-27

47.5xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-27
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
- 10-Q for 2025, filed 2026-08-07
- 10-K for 2025, filed 2026-02-27
- 10-Q for 2025, filed 2026-08-07
The filing itself
46.4%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
The filing itself
18.2%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-02-27
- 10-Q for 2025, filed 2026-08-07
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Price is the furthest below its sector's middle: 0.13 against 0.37 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.50x

1.27x

0.66x

n/a

3.19x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

4 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-02-27

Sales1.50x
Its own average over 10 years, 179.0M.
Profit1.27x
Its own average over 10 years, 97.7M.
Free cash flow0.66x
Its own average over 10 years, 73.7M.
Debtn/a
Its own average over 1 year, 650.3M.
Price3.19x
Its own average over 11 years, 99. Market data, 2026-11-04

Price is furthest from its own average, at 3.19 times.

The filed years, as a table

Each line is 100 at 2016-12-31, the first year we hold.

Filed year	Sales	Shares in issue
2016-12-31	100.0	100.0
2017-12-31	129.5	112.7
2018-12-31	230.7	115.5
2019-12-31	110.4	94.8
2020-12-31	150.1	50.4
2021-12-31	221.7	51.6
2022-12-31	180.1	50.5
2023-12-31	120.5	53.2
2024-12-31	153.4	54.8
2025-12-31	246.0	60.8

How sales was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0000886163-26-000006
Reported in: USD

The filing itself

How shares in issue was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0000886163-26-000006
Reported in: USD

The filing itself

Figures behind the shape

Growth

10.4%

faster is higher, placed against 4,950 companies as of 2026-11-07

Five-year revenue growth rate10.4%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
One-year change in net income3186.6%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Returns on capital

12.2%

higher is higher, placed against 5,089 companies as of 2026-11-07

Return on invested capitaln/a
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
- 10-Q for 2025, filed 2026-08-07
- 10-K for 2025, filed 2026-02-27
- 10-Q for 2025, filed 2026-08-07
The filing itself
Return on equity12.2%
Net Income / Shareholders' Equity x 100
Source
computed
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-02-27
- 10-Q for 2025, filed 2026-08-07
The filing itself
Return on assets8.0%
Net Income / Total Assets x 100
Source
computed
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-02-27
- 10-Q for 2025, filed 2026-08-07
The filing itself

Margins

15.3%

wider is higher, placed against 3,412 companies as of 2026-11-07

Gross marginn/a
We do not hold this figure for this company, so there is nothing to place.
Gross Profit / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
The filing itself
Operating margin15.3%
Operating Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
The filing itself
Net margin46.4%
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
The filing itself
Free cash flow margin18.2%
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
The filing itself

Price

47.5x

cheaper is higher, placed against 4,362 companies as of 2026-11-07

Price to earnings47.5x
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-27
The filing itself
Price to book6.1x10-Q for 2025, filed 2026-08-07
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Fiscal year
2025
Accession
0000886163-26-000044
Reported in
USD
- computed
- 10-Q for 2025, filed 2026-08-07
- computed
- 10-K for 2025, filed 2026-02-27
The filing itself
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
- 10-Q for 2025, filed 2026-08-07
- 10-K for 2025, filed 2026-02-27
The filing itself
Price to sales ratio23.2x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
The filing itself

Safety

22.23

safer is higher, placed against 3,227 companies as of 2026-11-07

Debt to equityn/a
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-02-27
- 10-Q for 2025, filed 2026-08-07
The filing itself
Current ratio22.2310-Q for 2025, filed 2026-08-07
Current Assets / Current Liabilities
Source
computed
Fiscal year
2025
Accession
0000886163-26-000044
Reported in
USD
- 10-Q for 2025, filed 2026-08-07
- 10-Q for 2025, filed 2026-08-07
The filing itself
Interest coverage8.7x
Operating Income / Interest Expense
Source
computed
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
The filing itself
Altman Z-Score8.28
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-07
Reported in
USD
- Computed from the 10-K for 2025, filed 2026-02-27
- Computed from the 10-K for 2025, filed 2026-02-27
- Computed from the 10-K for 2025, filed 2026-02-27
- Computed from the 10-K for 2025, filed 2026-02-27
- Computed from the 10-K for 2025, filed 2026-02-27

What it pays out

n/a

We do not hold this figure for this company, so there is nothing to place.

more, and better covered, is higher, with no cohort held

Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-02-27
- Computed from the 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
The filing itself
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.